TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma

Esther C. Yoon; Gang Wang; Bryce Parkinson; Lei Huo; Yan Peng; Jing Wang; Taylor Salisbury; Yun Wu; Hui Chen; Constance T. Albarracin; Erika Resetkova; Lavinia P. Middleton; Savitri Krishnamurthy; Qiong Gan; Hongxia Sun; Xiao Huang; Tiansheng Shen; Wei Chen; Anil V. Parwani; Aysegul A. Sahin; Zaibo Li; Qingqing Ding

doi:10.1016/j.humpath.2022.04.006

TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma

Esther C. Yoon, Gang Wang, Bryce Parkinson, Lei Huo, Yan Peng, Jing Wang, Taylor Salisbury, Yun Wu, Hui Chen, Constance T. Albarracin, Erika Resetkova, Lavinia P. Middleton, Savitri Krishnamurthy, Qiong Gan, Hongxia Sun, Xiao Huang, Tiansheng Shen, Wei Chen, Anil V. Parwani, Aysegul A. SahinZaibo Li, Qingqing Ding

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

A diagnostic dilemma can be encountered when primary triple-negative breast carcinoma (TNBC) without an in situ component or metastatic TNBCs lose the currently used organ-specific marker such as GATA3, raising concerns about metastatic carcinoma from other sites. In the current study, we compared the newly identified breast marker TRPS1 with currently used breast markers GATA3 and SOX10 in whole-tissue sections from 315 cases of various subtypes of TNBC. TRPS1 was highly expressed in 100% of triple-negative primary and metastatic invasive lobular carcinomas, 99% of triple-negative primary and metastatic invasive breast carcinoma of no special type (IBC-NST), and 95% of metaplastic breast carcinomas. In contrast, GATA3 and SOX10 were expressed in 94% and 0% of invasive lobular carcinomas, 63% and 74% of IBC-NST, and 50% and 49% of metaplastic breast carcinomas, respectively. For special-type TNBCs, both TRPS1 and GATA3 were negative in acinic cell carcinomas, most cribriform adenoid cystic carcinomas, and neuroendocrine carcinomas, but positive in secretory carcinomas. Triple-negative apocrine carcinoma was the only subtype of TNBC with positive GATA3 but negative TRPS1. These data indicate that TRPS1 is a highly sensitive marker for TNBCs with positivity not only in GATA3/SOX10-positive TNBCs but also in almost all GATA3/SOX10-negative TNBCs.

Original language	English (US)
Pages (from-to)	97-107
Number of pages	11
Journal	Human Pathology
Volume	125
DOIs	https://doi.org/10.1016/j.humpath.2022.04.006
State	Published - Jul 2022

Keywords

GATA3
Invasive breast carcinoma of no special type
Invasive lobular carcinoma
Metaplastic carcinoma
SOX10
TRPS1
Triple-negative breast carcinoma

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1016/j.humpath.2022.04.006

Cite this

Yoon, E. C., Wang, G., Parkinson, B., Huo, L., Peng, Y., Wang, J., Salisbury, T., Wu, Y., Chen, H., Albarracin, C. T., Resetkova, E., Middleton, L. P., Krishnamurthy, S., Gan, Q., Sun, H., Huang, X., Shen, T., Chen, W., Parwani, A. V., ... Ding, Q. (2022). TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Human Pathology, 125, 97-107. https://doi.org/10.1016/j.humpath.2022.04.006

Yoon, EC, Wang, G, Parkinson, B, Huo, L, Peng, Y, Wang, J, Salisbury, T, Wu, Y, Chen, H, Albarracin, CT, Resetkova, E, Middleton, LP, Krishnamurthy, S, Gan, Q, Sun, H, Huang, X, Shen, T, Chen, W, Parwani, AV, Sahin, AA, Li, Z & Ding, Q 2022, 'TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma', Human Pathology, vol. 125, pp. 97-107. https://doi.org/10.1016/j.humpath.2022.04.006

@article{1cd5265f431149b58f4bf36068813eed,

title = "TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma",

abstract = "A diagnostic dilemma can be encountered when primary triple-negative breast carcinoma (TNBC) without an in situ component or metastatic TNBCs lose the currently used organ-specific marker such as GATA3, raising concerns about metastatic carcinoma from other sites. In the current study, we compared the newly identified breast marker TRPS1 with currently used breast markers GATA3 and SOX10 in whole-tissue sections from 315 cases of various subtypes of TNBC. TRPS1 was highly expressed in 100% of triple-negative primary and metastatic invasive lobular carcinomas, 99% of triple-negative primary and metastatic invasive breast carcinoma of no special type (IBC-NST), and 95% of metaplastic breast carcinomas. In contrast, GATA3 and SOX10 were expressed in 94% and 0% of invasive lobular carcinomas, 63% and 74% of IBC-NST, and 50% and 49% of metaplastic breast carcinomas, respectively. For special-type TNBCs, both TRPS1 and GATA3 were negative in acinic cell carcinomas, most cribriform adenoid cystic carcinomas, and neuroendocrine carcinomas, but positive in secretory carcinomas. Triple-negative apocrine carcinoma was the only subtype of TNBC with positive GATA3 but negative TRPS1. These data indicate that TRPS1 is a highly sensitive marker for TNBCs with positivity not only in GATA3/SOX10-positive TNBCs but also in almost all GATA3/SOX10-negative TNBCs.",

keywords = "GATA3, Invasive breast carcinoma of no special type, Invasive lobular carcinoma, Metaplastic carcinoma, SOX10, TRPS1, Triple-negative breast carcinoma",

author = "Yoon, {Esther C.} and Gang Wang and Bryce Parkinson and Lei Huo and Yan Peng and Jing Wang and Taylor Salisbury and Yun Wu and Hui Chen and Albarracin, {Constance T.} and Erika Resetkova and Middleton, {Lavinia P.} and Savitri Krishnamurthy and Qiong Gan and Hongxia Sun and Xiao Huang and Tiansheng Shen and Wei Chen and Parwani, {Anil V.} and Sahin, {Aysegul A.} and Zaibo Li and Qingqing Ding",

note = "Funding Information: We thank Sarah Bronson, ELS, Scientific Editor, in the Research Medical Library at The University of Texas MD Anderson for her editorial assistance with this manuscript. This study was supported by MD Anderson Department of Pathology faculty grant and Division of Pathology and Laboratory Medicine research fund to Q. D. Author contributions: E. C. Y., A. A. S., Z. L., and Q. D. performed study concept and design and writing; G. W., B. P., L. H., Y. P., J. W., T. S., Y. W., and H. C. performed experiments, data collection, and analysis; C. T. A., E. R., L. P. M., S. K., Q. G., H. S., X. H., T. S., W. C., and A. V. P. contributed to analysis and interpretation of data and review and revision of the paper. All authors read and approved the final paper. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.humpath.2022.04.006",

language = "English (US)",

volume = "125",

pages = "97--107",

journal = "Human Pathology",

issn = "0046-8177",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma

AU - Yoon, Esther C.

AU - Wang, Gang

AU - Parkinson, Bryce

AU - Huo, Lei

AU - Peng, Yan

AU - Wang, Jing

AU - Salisbury, Taylor

AU - Wu, Yun

AU - Chen, Hui

AU - Albarracin, Constance T.

AU - Resetkova, Erika

AU - Middleton, Lavinia P.

AU - Krishnamurthy, Savitri

AU - Gan, Qiong

AU - Sun, Hongxia

AU - Huang, Xiao

AU - Shen, Tiansheng

AU - Chen, Wei

AU - Parwani, Anil V.

AU - Sahin, Aysegul A.

AU - Li, Zaibo

AU - Ding, Qingqing

N1 - Funding Information: We thank Sarah Bronson, ELS, Scientific Editor, in the Research Medical Library at The University of Texas MD Anderson for her editorial assistance with this manuscript. This study was supported by MD Anderson Department of Pathology faculty grant and Division of Pathology and Laboratory Medicine research fund to Q. D. Author contributions: E. C. Y., A. A. S., Z. L., and Q. D. performed study concept and design and writing; G. W., B. P., L. H., Y. P., J. W., T. S., Y. W., and H. C. performed experiments, data collection, and analysis; C. T. A., E. R., L. P. M., S. K., Q. G., H. S., X. H., T. S., W. C., and A. V. P. contributed to analysis and interpretation of data and review and revision of the paper. All authors read and approved the final paper. Publisher Copyright: © 2022

PY - 2022/7

Y1 - 2022/7

N2 - A diagnostic dilemma can be encountered when primary triple-negative breast carcinoma (TNBC) without an in situ component or metastatic TNBCs lose the currently used organ-specific marker such as GATA3, raising concerns about metastatic carcinoma from other sites. In the current study, we compared the newly identified breast marker TRPS1 with currently used breast markers GATA3 and SOX10 in whole-tissue sections from 315 cases of various subtypes of TNBC. TRPS1 was highly expressed in 100% of triple-negative primary and metastatic invasive lobular carcinomas, 99% of triple-negative primary and metastatic invasive breast carcinoma of no special type (IBC-NST), and 95% of metaplastic breast carcinomas. In contrast, GATA3 and SOX10 were expressed in 94% and 0% of invasive lobular carcinomas, 63% and 74% of IBC-NST, and 50% and 49% of metaplastic breast carcinomas, respectively. For special-type TNBCs, both TRPS1 and GATA3 were negative in acinic cell carcinomas, most cribriform adenoid cystic carcinomas, and neuroendocrine carcinomas, but positive in secretory carcinomas. Triple-negative apocrine carcinoma was the only subtype of TNBC with positive GATA3 but negative TRPS1. These data indicate that TRPS1 is a highly sensitive marker for TNBCs with positivity not only in GATA3/SOX10-positive TNBCs but also in almost all GATA3/SOX10-negative TNBCs.

AB - A diagnostic dilemma can be encountered when primary triple-negative breast carcinoma (TNBC) without an in situ component or metastatic TNBCs lose the currently used organ-specific marker such as GATA3, raising concerns about metastatic carcinoma from other sites. In the current study, we compared the newly identified breast marker TRPS1 with currently used breast markers GATA3 and SOX10 in whole-tissue sections from 315 cases of various subtypes of TNBC. TRPS1 was highly expressed in 100% of triple-negative primary and metastatic invasive lobular carcinomas, 99% of triple-negative primary and metastatic invasive breast carcinoma of no special type (IBC-NST), and 95% of metaplastic breast carcinomas. In contrast, GATA3 and SOX10 were expressed in 94% and 0% of invasive lobular carcinomas, 63% and 74% of IBC-NST, and 50% and 49% of metaplastic breast carcinomas, respectively. For special-type TNBCs, both TRPS1 and GATA3 were negative in acinic cell carcinomas, most cribriform adenoid cystic carcinomas, and neuroendocrine carcinomas, but positive in secretory carcinomas. Triple-negative apocrine carcinoma was the only subtype of TNBC with positive GATA3 but negative TRPS1. These data indicate that TRPS1 is a highly sensitive marker for TNBCs with positivity not only in GATA3/SOX10-positive TNBCs but also in almost all GATA3/SOX10-negative TNBCs.

KW - GATA3

KW - Invasive breast carcinoma of no special type

KW - Invasive lobular carcinoma

KW - Metaplastic carcinoma

KW - SOX10

KW - TRPS1

KW - Triple-negative breast carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85128989423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128989423&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2022.04.006

DO - 10.1016/j.humpath.2022.04.006

M3 - Article

C2 - 35413381

AN - SCOPUS:85128989423

SN - 0046-8177

VL - 125

SP - 97

EP - 107

JO - Human Pathology

JF - Human Pathology

ER -

TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this